Skip to main navigation
Adamis
  • Contact Us
Select Page
  • About
    • Overview
    • Management
    • Board of Directors
  • Customized Medications
  • Products
  • Pipeline
    • Specialty Pharmaceuticals
    • APC – 1000
    • APC – 4000
    • APC – 6000
    • APC – 8000
  • Investors

    Investor Relations

    • Investors
    • Overview
    • News Releases
    • Stock Information
    • SEC Filings
    • Events and Presentations
    • Email Alerts
  • Careers
    • Partnerships
  • Contact Us

SEC Filing Details

Investor Relations

  • Investors
  • Overview
  • News Releases
  • Stock Information
  • SEC Filings
  • Events and Presentations
  • Email Alerts

Tools

  • Print Page

SEC Filing Details

Document Details

Form
4
Filing Date
Nov 20, 2019
Document Date
Nov 18, 2019
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Adamis Pharmaceuticals Corporation
Issuer
ADAMIS PHARMACEUTICALS CORP
Filer
Moss Ronald B.

Filing Formats

View HTML
Download PDF
Download DOC
Adamis
  • About

  • Management
  • Board of Directors
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a specialty biopharmaceutical company focused on developing and commercializing pharmaceutical products in the therapeutic areas of respiratory disease and allergy.
  • Customized Medications

  • Products

  • Pipeline

  • Specialty Pharmaceuticals
    • APC – 6000
    • APC – 8000
  • Metered Dose Inhalers
    • APC – 1000
  • Dry Powder Inhaler Platform
    • APC – 4000
  • Partnerships

Investor Relations

  • Investors
  • Overview
  • News Releases
  • Stock Information
  • SEC Filings
  • Events and Presentations
  • Email Alerts
  • Careers
  • Partnerships
  • Contact Us

858.997.2400
  • Privacy Statement
  • Terms of Use

2019 Copyright Adamis Pharmaceuticals Corporation